ProFound Therapeutics ProFound Therapeutics is leveraging previously undiscovered human proteins to develop treatments for a wide range of diseases
By leveraging patent thickets aimed at extending the market monopolies on their blockbuster drugs, these companies seek to maximize revenue streams while delaying the entry of low-cost generic alternatives
Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors
in Diabetes, Obesity and Metabolism in early 2026 (the Wiley DOM TRIUMPH design paper), and the individual trial identifiers are public on ClinicalTrials.gov
To better understand the human side of the GLP-1 divide, The Health Management Academy surveyed 1,827 Americans in November 2025 to capture the real-world impact of the GLP-1 divide, highlighting the emotional, social, and financial toll it takes across different incomes and between men and women